子宫腺肌瘤术后序贯应用GnRH-a和优思明疗效观察

发布时间：2018-05-30 19:38

本文选题：子宫腺肌瘤 + GnRH-a　；参考：《医学与哲学(B)》2017年11期

【摘要】：序贯应用促性腺激素释放激素激动剂(GnRH-a),屈螺酮炔雌醇(优思明)做为子宫腺肌瘤挖除术后后续治疗方案的治疗效果。选取2010年1月到2013年12月之间在柳州市工人医院妇产科行腹腔镜或开腹子宫腺肌瘤挖除术患者,按术后治疗方案分为A组(GnRH-a)、B组(GnRH-a+优思明)和C组(观察),随访2年对比各组疗效。结果 A组、B组、C组症状复发率分别为12%、4%、27%。术后各组子宫体积明显缩小,月经量评分(PBAC评分)明显下降(P0.05),随访第1年及第2年A、B组PBAC评分及VAS疼痛评分明显低于C组。B组子宫缩小比例明显大于C组。子宫腺肌瘤病灶切除术后应用GnRH-a能缓解痛经,减少月经量,使子宫体积缩小,序贯联合应用优思明可减轻GnRH-a副作用,为子宫腺肌瘤患者带来更好的临床治疗策略,降低远期复发率。
[Abstract]:The sequential application of gonadotropin releasing hormone agonist (GnRH-a), androparonne estradiol (Yosmin) as a follow-up treatment for uterine adenomyoma. From January 2010 to December 2013, patients undergoing laparoscopy or laparotomy of adenomyoma of uterus in Liuzhou Workers' Hospital, gynecology and obstetrics, were selected. The patients were divided into two groups: group A (GnRH-a) and group C (2 years follow-up). Results the recurrence rate of symptoms in group A and group B were 12 and 27, respectively. After operation, the uterine volume and menstrual volume score decreased significantly (P 0.05). The PBAC score and VAS pain score in group A were significantly lower than those in group C and group C in the first and second year of follow-up. The ratio of uterine contraction in group B was significantly lower than that in group C (P < 0.05). GnRH-a can relieve dysmenorrhea, reduce menstrual volume and reduce uterine volume after resection of adenomyoma of uterus. Sequential application of Yosemin can alleviate the side effects of GnRH-a and bring better clinical treatment strategy for patients with adenomyoma of uterus. Reduce the long term recurrence rate.
【作者单位】：广西医科大学第四附属医院妇产科;
【基金】：2016年广西壮族自治区卫生和计划生育委员会自筹经费科研课题(Z2016182)
【分类号】：R737.33

【相似文献】